HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo by Segura-Pacheco, Blanca et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Genetic Vaccines and Therapy
Open Access Research
HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo
Blanca Segura-Pacheco†, Berenice Avalos†, Edgar Rangel, Dora Velazquez and 
Gustavo Cabrera*
Address: Vectorology and Gene Therapy Laboratory, National Cancer Institute, Av. San Fernando No 22, Del. Tlalpan, CP 14080, Mexico City, 
Mexico
Email: Blanca Segura-Pacheco - segura_blanca@yahoo.com; Berenice Avalos - bjar_fernandez@hotmail.com; 
Edgar Rangel - raledg@hotmail.com; Dora Velazquez - doris_oscuridad@yahoo.com.mx; Gustavo Cabrera* - g.cabrera@yahoo.com
* Corresponding author    †Equal contributors
Abstract
Background: The presence of CAR in diverse tumor types is heterogeneous with implications in
tumor transduction efficiency in the context of adenoviral mediated cancer gene therapy.
Preliminary studies suggest that CAR transcriptional regulation is modulated through histone
acetylation and not through promoter methylation. Furthermore, it has been documented that the
pharmacological induction of CAR using histone deacetylase inhibitor (iHDAC) compounds is a
viable strategy to enhance adenoviral mediated gene delivery to cancer cells in vitro. The
incorporation of HDAC drugs into the overall scheme in adenoviral based cancer gene therapy
clinical trials seems rational. However, reports using compounds with iHDAC properties utilized
routinely in the clinic are pending. Valproic acid, a short chained fatty acid extensively used in the
clinic for the treatment of epilepsy and bipolar disorder has been recently described as an effective
HDAC inhibitor at therapeutic concentrations.
Methods: We studied the effect of valproic acid on histone H3 and H4 acetylation, CAR mRNA
upregulation was studied using semiquantitative PCR and adenoviral transduction on HeLa cervical
cancer cells, on MCF-7 breast cancer cells, on T24 transitional cell carcinoma of the bladder cells.
CAR mRNA was studied using semiquantitative PCR on tumor tissue extracted from patients
diagnosed with cervical cancer treated with valproic acid.
Results: CAR upregulation through HDAC inhibition was observed in the three cancer cell lines
with enhancement of adenoviral transduction. CAR upregulation was also observed in tumor
samples obtained from patients with cervical cancer treated with therapeutic doses of valproic acid.
These results support the addition of the HDAC inhibitor valproic acid to adenoviral mediated
cancer gene therapy clinical trials to enhance adenoviral mediated gene delivery to the tumor cells.
Background
The identification of the coxsackie adenovirus receptor
(CAR) and the description of its gene structure and the
sequences that regulate its expression has furthered the
understanding of CARs role in cellular biology, the aden-
oviral infection process and thus on enhancing the poten-
tial for therapeutic success in the context of adenovirus
mediated cancer gene therapy [1-6]. Additionally, it has
become apparent that expression of CAR is heterogeneous
in diverse tumor types with implications in tumor trans-
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duction efficiency in the context of adenovirus based can-
cer gene therapy [7-10]. In this regard, initial findings
suggest that CAR transcriptional regulation is modulated
through local remodeling of the chromatin structure,
mainly through histone acetylation and not through pro-
moter methylation even though the putative promoter
contains several CpG di-nucleotides [11]. Various groups
have corroborated this finding utilizing various histone
deacetylace inhibitors (iHDAC) to induce CAR gene
expression, increase CAR presence on the surface of the
tumor cells and thus enhance adenoviral transduction
[12-14]. In addition to its CAR inducing potential,
iHDACs posses two additional properties that would jus-
tify their addition to anti cancer gene therapy clinical tri-
als: 1) iHDACs enhance the expression of the therapeutic
gene [15-17]and 2) iHDACs display anti-neoplastic prop-
erties [18-23]. Thus, the incorporation of iHDAC com-
pounds into the overall scheme in adenovirus mediated
cancer gene therapy clinical trials seems well founded.
However, reports using compounds with iHDAC proper-
ties utilized routinely in the clinic to induce the expres-
sion of CAR are pending. Valproic acid (VPA), a short
chained fatty acid extensively used in the clinic to treat
epilepsy and bipolar disorder has been described as an
effective HDAC inhibitor [24-27]. In the present report,
we studied the effect of VPA on CAR expression on HeLa
cervical cancer cells, on MCF-7 breast cancer cells, on T24
transitional cell carcinoma of the bladder cells and on
tumor biopsies from patients with cervical cancer treated
with VPA.
Methods
Cell lines, cell culture and reagents
The cervical cancer cell line HeLa, the breast cancer cell
line MCF-7 and the T24 transitional cell carcinoma cell
line were obtained from American Type Culture Collec-
tion. Cells were grown in DMEM F12 supplemented with
10% fetal bovine serum (FBS) and 1× penicillin-strepto-
mycin (Invitrogen, Carlsbad, CA) at 37°C and 5% CO2.
DMEM-F12 culture media and FBS were purchased from
Invitrogen (Carlsbad, CA). Trichostatin (TSA) was
obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Valproic acid was obtained from M.P.I Pharmaceu-
tica GmbH, (Hamburg). OPTIMEM was obtained from
Invitrogen (Carlsbad, CA)
Recombinant Adenovirus
The adenovirus Ad-CMV-Luc encodes the luciferase gene
driven by the cytomegalovirus (CMV) promoter and was
a kind gift from Dr. David Curiel at the University of Ala-
bama at Birmingham. Adenoviral preparations and titer-
ing were performed as previously described [28].
Histone deacetylase assay
All cell lines were plated in T-150 flasks at 80% conflu-
ency. The three cell lines were treated with 5 µM TSA.
HeLa cells were treated with 2 mM VPA, T24 cells 1 mM
VPA and MCF7 cells 1 mM. 12 hours after treatment cells
were harvested, pelleted and washed with PBS solution,
RIPA buffer was added and protein quantification was
performed using the bicinchoninic acid and cooper (II)
sulfate method (Sigma-Aldridch St. Louis, MO). HDAC
activity assay was performed using a colorimetric com-
mercial kit from BioVision (BioVision Research Products,
Mountain View, CA) following the manufacturers instruc-
tions. Briefly, 50 µg of total protein from treated cells were
diluted in 85 µL of ddH2O; 10 µL of 10× HDAC assay
buffer was added followed by the addition of 5 µL of the
colorimetric substrate; samples were incubated at 37°C
for 1. The reaction was stopped by adding 10 µL of lysine
developer and left for an additional 30 min at 37°C. Sam-
ples were then read in an ELISA plate reader Labsystems
Multiskan MS (Life Science International, Helsinki) at 405
nm. HDAC activity was expressed as percentage of activity.
The kit contains negative and positive controls that con-
sist of nuclear extract of HeLa treated or not with TSA,
respectively.
Acid extraction of proteins and western blot analysis
All cell lines were plated in T-150 flasks at 80% of conflu-
ency. The three cell lines were treated with the iHDACs as
previously described. 12 hours after treatment, the cells
were harvested, pelleted and washed with PBS for further
acid extraction of histones with modifications [23]. Cells
were then suspended in five volumes of lysis buffer [10
mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.5
mM DTT, and 1.5 mM phenylmethylsulfonyl fluoride]
and hydrochloride acid at a final concentration of 0.2 M
and subsequently lysed on ice for 30 min. After centrifu-
gation at 11,000 × g for 10 min at 4°C, the cell superna-
tant fraction that contained acid-soluble proteins was
retained. Supernatant was dialyzed against 200 mL of 0.1
M acetic acid twice for 1–2 h each and then dialyzed
against 200 mL of H2O for 1 h, 3 h, and overnight. Dialy-
sis was performed using a Spectra/Pore 3 Dialysis Mem-
branes 3,500 MWCO (Spectrum Laboratories, Inc.,
Rancho Dominguez, CA). Five µg of acid proteins were
analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE)/immunoblotting with anti-
bodies recognizing acetylated and non acetylated histones
(rabbit polyclonal IgG, anti-acetyl-histone and non-
acetyl-histone H4, and rabbit polyclonal IgG anti-acetyl-
histone and non-acetyl-histone H3; Upstate Biotechnol-
ogy, Lake Placid, NY). Protein samples were separated
along with molecular weight markers (Bio-Rad, Hercules,
CA) in 12% polyacrylamide gels. Gels were transferred
onto 0.2 µm PVDF membranes (Bio-Rad, Hercules CA).
Gel loading equivalence was confirmed by CoomassieGenetic Vaccines and Therapy 2007, 5:10 http://www.gvt-journal.com/content/5/1/10
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blue stain (Sigma, St Louis, MO). Species-specific immu-
noglobulin G-horseradish peroxidase (IgG-HRP) second-
ary antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz CA, USA). Blots were devel-
oped with chemiluminescent substrate (BioRad Hercules
CA) and autoradiography was performed utilizing X-
OMAT film (Kodak, Rochester, NY).
CAR RT-PCR
All the cell lines were plated in T-150 flasks at 80% con-
fluency. HeLa cells were treated with 2 mM VPA, T24 cells
1 mM VPA and MCF7 cells 1 mM. Twelve and 24 hours
after treatment, the cells were harvested, pelleted and
washed with PBS. RNA from drug-treated and untreated
cells was obtained using TRIzol Reagent (Invitrogen,
Carlsbad CA). One µg of total RNA was used for reverse
transcription, which was performed with a RNA PCR Kit
(Applied Biosystems, Branchburg NJ) following the man-
ufacturer instructions. For CAR mRNA detection, the fol-
lowing primers were used: sense: 
5'-GCCTTCAGGTGCGAGATGTTAC-3' antisense: 5'-TCG-
CACCCATTCGACTTAGA-3' in a total reaction volume of
20 µl. The PCR conditions were: 94°C/5 min, followed by
27 cycles at 94°C/30 s, 60°C/30 s, and 72°C/1 min. As
control for the amount and integrity of the mRNA, the
expression of the GAPDH gene was analyzed using the fol-
lowing primers sense: 5'-GAAGGTGAAGGTCGGAGTC-3'
anti-sense: 5'-CAAGATGGTGATGGGATTTC-3' PCR con-
ditions were: 94°C/5 min, followed by 27 cycles at 94°C/
30 s, 55°C/30 s, and 72°C/30 s.
Luciferase PCR
Two groups of 2 × 105 cells were plated in triplicate in 6
well plates with complete media. 24 hrs post plating, cells
were treated 2 mM VPA for HeLa; 1 mM VPA for the T24
cell line and 1 mM VPA for MCF7. Twenty four hours after
treatment, one group was harvested and counted. MOI
was then calculated for the group that remained in cul-
ture. Cells were then transduced for 1 hour with
Ad.CMV.Luc in serum free OPTIMEM (Invitrogen,
Carlsbad CA, USA) with a MOI of 100 for HeLa and T24
cell lines and 10 for MCF-7 cells. After 1 hour of adenovi-
ral transduction, the OPTIMEM was removed, cells were
washed 2× with PBS, cells were then harvested and pel-
leted with 500 µl of lysis buffer (10 mM Tris pH 7.8, 20
mM EDTA and 0.5% SDS) for phenol-chloroform DNA
extraction. The Luciferase gene was amplified using the
following primers: sense 5'-ATGGAAGACGCCAAAAA-
CATAAAG-3' antisense 5'-AAAACCGGGAGGTAGATGA-
GATGT-3' in a total reaction volume of 20 µl. PCR
conditions were: 94°C for 5 min, followed by 25 cycles at
94°C for 30 s, 50°C for 30 s, and 72°C for 30 s and 7 min
at 72°C extension. As control for the amount and integrity
of the DNA, the expression of the β-actin gene was ana-
lysed using the following primers: sense 5'-ATCTGGCAC-
CACACCTTCTACAAT-3' anti-sense 
5'-CCGTCACCGGAGTCCATCA-3' PCR conditions were
94°C for 5 min, followed by 25 cycles at 94°C for 30 s,
60°C for 30 s, and 72°C for 30 s and 7 min at 72°C exten-
sion.
Luciferase activity
Two groups of 2 × 105 cells were plated in triplicate in 6
well plates with complete media. 24 hrs post plating, cells
were treated with 2 mM VPA for HeLa; 1 mM VPA for the
T24 cell line and 1 mM VPA for MCF7. Twenty four hours
after treatment, one group of cells was harvested and
counted. MOI was then calculated for the group that
remained in culture. Cells were then transduced for 1
hour with Ad.CMV.Luc in serum free OPTIMEM with the
following MOIs: HeLa 100, T24 100, MCF-7 10. One hour
after adenoviral transduction, OPTIMEM was removed,
cells were washed 2× with PBS and complete media was
then added. Forty eight hours post adenoviral transduc-
tion cells were harvested and resuspended in 50 µl of luci-
ferase lysis buffer (Promega Inc., Madison, WI). Protein
concentration was then determined using the bicin-
choninic acid and cooper (II) sulfate method (Sigma-
Aldridch St. Louis MO) and luciferase activity was meas-
ured as indicated by the manufacturer using a luminome-
ter (Turner Designs, Sunnyvale, CA).
Clinical samples and VPA dosing
RNA samples before and after VPA treatment were a kind
gift from Dr. Alfonso Dueñas from a previously reported
phase I clinical cervical cancer trial conducted at the
National Cancer Institute, Mexico City, Mexico [23].
Briefly, biopsies were taken from areas with visible macro-
scopic cervical tumor using a sterile biopsy punch the day
before VPA treatment. After tumor sampling, patients
were started on oral valproic acid for a five-day period at
40 mg/kg. The total dose was divided in three administra-
tions every 8 h (8 AM, 4 PM and 12 PM) per oral route in
enteric-coated tablets of 200 mg. The post-treatment
biopsy was taken at the sixth day post VPA treatment early
in the morning, 8 to 10 hours after the last dose of VPA.
Part of the biopsy was sent to the National Cancer Insti-
tutes Pathology Department for routine hematoxilin &
eosin processing and observation. The remaining biopsy
specimen was immediately frozen at -20°C for biological
analyses. Patient 1 corresponds to patient 11, patient 2
corresponds to patient 12, patient 3 corresponds to
patient 9, and patient 4 corresponds to patient 10; figure
3, reference [23].
Statistical Analysis
Data from the luciferase reporter gene expression experi-
ments was evaluated for statistical significance using the
Students t test. Values less than 0.05 were considered sig-
nificant.Genetic Vaccines and Therapy 2007, 5:10 http://www.gvt-journal.com/content/5/1/10
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Results
Valproic acid inhibits HDACs and hyperacetylates H3 and 
H4 histones
We initially confirmed previous reports which described
VPA as an effective HDAC inhibitor. We selected a dose in
which a 20% growth inhibition was observed (data not
shown), we utilized a commercially available viability kit
to determine the growth inhibitor concentration of VPA
(MTT assay, Promega Corp, Madison, WI). Once the dose
had been selected, HDAC inhibition and H3 and H4
hyperacetylation were assayed on the breast cancer cell
line MCF-7, the transitional cell carcinoma of the bladder
cell line T24, and cervical cancer cell line HeLa using dif-
ferent concentrations of VPA. Trichostatin A (TSA), a
known potent HDAC inhibitor was used as a positive con-
trol. The selected doses of valproic acid for each cell line
where capable of inhibiting HDAC activity within the first
12 hours as seen in figure 1a. This inhibition correlated
with an increment in histone H3 and H4 acetylation. Our
results suggest that valproic acid induced hypercetylation
occured mainly on histone H4 while TSA induced hyper-
acetylation was observed on histone H3 (figure 1b).
Valproic acid induces CAR expression in vitro
Given the potential use of VPA as a CAR upregulator in a
clinical scenario, two potential VPA start-up times (12 or
24 hrs) prior to adenoviral gene therapy were evaluated.
Twelve and twenty four hours post VPA pharmacological
treatment, total mRNA was extracted, reverse transcription
was performed and semi-quantitative PCR was done to
assess changes on CAR mRNA levels. The HeLa and MCF7
cancer cell lines treated with valproic acid displayed a
transcriptional upregulation in CAR mRNA levels as seen
in figure 2. Our preliminary in vitro results suggest that
patients could be started on VPA CAR induction treatment
as early as 12 or 24 hours prior to adenoviral gene therapy.
CAR upregulation enhances adenoviral transduction in 
vitro
Once determined that CAR transcription was induced by
HDAC inhibition, we studied if adenoviral infection was
enhanced in CAR induced cells. To this end, two sets of
experiments were designed. One set of experiments deter-
mined if adenoviral genome entry was enhanced in phar-
macologically induced CAR cells. The other group of
experiments assessed the overall effect on reporter gene
expression levels in cells in which CAR had been pharma-
cologically induced. The results in the first set of experi-
VPA mediated CAR transcriptional induction enhances adenoviral transduction and transgene expression on HeLa, T24 and  MCF7 cell lines Figure 3
VPA mediated CAR transcriptional induction enhances adenoviral transduction and transgene expression on HeLa, T24 and 
MCF7 cell lines. A) Cells were treated with VPA as described in materials and methods. Twenty-four hours after treatment, 
cells were then transduced for 1 hour with Ad.CMV.Luc. 1 hour post adenoviral transduction, cells were washed and har-
vested for luciferase gene semi-quantitative PCR analysis. B) Cells were treated with VPA as described in methods. Twenty 
four hours after pharmacological treatment cells were then transduced for 1 hour with Ad.CMV.Luc. 48 hours post adenoviral 
transduction cells were harvested and assayed for luciferase activity. Asterisks indicate statistically significant changes among 
control vs VPA groups (p < 0.05).Genetic Vaccines and Therapy 2007, 5:10 http://www.gvt-journal.com/content/5/1/10
Page 5 of 8
(page number not for citation purposes)
ments indicate that adenoviral reporter gene entered the
cells more efficiently in valproic acid treated cells when
compared to the untreated control cells as seen in figure 3
panel A. These results support the results in the second set
of experiments in which the levels of reporter activity cor-
relate with the higher quantity of adenoviral genome that
enter the cells in the treated groups as observed in figure 3
panel B (also see additional file 1).
CAR mRNA increment on tumor samples
Since tumor transfection efficiency is a rate limiting step
in adenoviral based cancer gene therapy, the clinical
application of HDAC inhibitors to induce CAR expression
prior to adenoviral gene delivery in order increase tumor
transfection would seem rational. We thus studied VPA
mediated CAR upregulation on tumor samples obtained
from patients with cervical cancer before and after VPA
treatment. To this end, four samples of mRNA were made
available to us for CAR mRNA studies from a phase I clin-
ical study [23]. Patients diagnosed with cervical cancer
where treated with oral valproic acid as described in meth-
ods. Assessment of CAR mRNA levels was done using
semi-quantitative RT-PCR as previously described. Patient
1 corresponds to patient 11, patient 2 corresponds to
patient 12, patient 3 corresponds to patient 9, and patient
4 corresponds to patient 10 of figure 3, reference [23].
Results obtained from patients 1 and 2 showed an
increase in CAR as seen in figure 4. The samples from
patients 3 and 4 correspond to the patients with no
observable changes in HDAC activity and histone acetyla-
tion levels reported previously [23] this would provide a
potential explanation for the lack of CAR upregulation.
The in vitro results shown in figure 2, suggest that patients
could be started on VPA CAR induction treatment as early
as 12 or 24 hours prior to adenoviral gene therapy. The
results obtained from the clinical study suggest that
patients could undergo VPA CAR induction treatment five
days prior to adenoviral gene therapy. Further studies are
required to establish the optimal scheme and doses for
CAR upregulation in a clinical setting using VPA.
Discussion
The success in the clinical translation of gene therapy
strategies in the context of neoplastic disease depends on
addressing various core issues: 1) the implementation of
an effective anti-neoplastic strategy, 2) the efficient deliv-
ery of the strategy to the cells that constitute the primary
tumor mass, 3) obtaining optimal transcriptional levels of
the therapeutic gene and 4) expression of the putative
therapeutic gene for an optimal period of time. The suc-
cessful resolution of these four hurdles would be reflected
on the primary tumor mass and on the control of meta-
Effect of VPA on HDAC activity and histone H3 and H4 acetylation on HeLa, T24 and MCF7 cell lines Figure 1
Effect of VPA on HDAC activity and histone H3 and H4 acetylation on HeLa, T24 and MCF7 cell lines. Cell lines were treated 
with TSA and VPA as described in "Methods". Twelve hours post pharmacological treatment cells were harvested for A) 
HDAC activity and B) histone H3 and H4 western blot analysis. Coomasie stained gels were used for loading control.Genetic Vaccines and Therapy 2007, 5:10 http://www.gvt-journal.com/content/5/1/10
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static disease. Thus, it has become clear that efficient gene
delivery is a rate limiting step in cancer gene therapy [29].
Three general approaches have been devised to address
the delivery issue. First, through the modification of the
adenoviral fiber that would direct viral infection to a CAR
independent pathway [30,31]. The second approach pro-
poses controlling the adenoviral intratumoral dwelling
time in order to allow the optimal interaction of the ade-
novirus with CAR and integrins in order to enhance cell
transduction [32]. The third approach proposes the phar-
macological induction of CAR expression. In this regard,
initial studies of the CAR promoter suggest that CAR tran-
scriptional regulation is modulated through remodeling
of the chromatin structure, mainly through histone
acetylation and not through promoter methylation [11].
This approach has been further supported by the use of
compounds with HDAC inhibitory properties which
release CAR expression from HDAC-dependent transcrip-
tional repression. Various groups have thus shown that
the pharmacological induction of CAR is a viable strategy
in order to enhance adenoviral mediated gene delivery to
cancer cells [12-14]. The incorporation of HDAC inhibitor
drugs into the overall scheme in cancer gene therapy clin-
ical trials would thus seem rational. This would imply the
administration of routinely used pharmacological com-
pounds in the clinic with HDAC inhibitory properties. In
this regard, valproic acid is a short chained fatty acid
extensively used in the clinic to treat epilepsy and bipolar
disorder. VPA has been described as an effective HDAC
inhibitor at therapeutic concentrations [23]. The present
study demonstrates that clinically reachable serum con-
centrations of valproic acid increase CAR mRNA in two
distinct time points; 12 and 24 hours post pharmacologi-
cal treatment. These preliminary results suggest that
patients undergoing adenoviral based cancer gene therapy
could be started on VPA CAR induction treatment as early
as 12 or 24 hours prior to adenoviral therapy. In addition
to inducing CAR expression on tumor cell lines and
improving the vector delivery profile in vitro, we also
demonstrate that two out of four cervical cancer samples
obtained from patients treated for 5 days with clinically
reachable serum concentrations of valproic acid [23]
increased CAR mRNA. Further studies to establish the
optimal VPA doses, schemes and CAR induction windows
are required in order better determine VPAs role in aden-
oviral based cancer gene therapy. This would be the first
report documenting the pharmacological induction of
CAR utilizing a HDAC inhibitor compound in humans.
CAR mRNA transcriptional induction mediated by VPA Figure 2
CAR mRNA transcriptional induction mediated by VPA. 
Given the potential use of VPA as a CAR upregulator in a 
clinical scenario, two potential VPA start-up times (12 or 24 
hrs) prior to adenoviral gene therapy were evaluated. Twelve 
and twenty four hours post VPA pharmacological treatment, 
total mRNA was extracted, reverse transcription was per-
formed and semi-quantitative PCR was done to assess 
changes on CAR mRNA levels as described in methods. The 
HeLa and MCF7 cancer cell lines treated with valproic acid 
displayed upregulation in CAR mRNA levels. The GAPDH 
gene was used as the loading control for semi-quantification 
analysis.
Effect of VPA on CAR transcriptional induction on tumors from patients with grade II cervical cancer treated with VPA Figure 4
Effect of VPA on CAR transcriptional induction on tumors from patients with grade II cervical cancer treated with VPA. RNA 
samples before and after VPA treatment were obtained from a phase I cervical cancer trial. Pre-treatment biopsies were 
obtained the day before VPA treatment started. Patients were then started on oral magnesium valproate for a five-day period 
at 40 mg/kg. The post-treatment biopsy was taken at the sixth day post VPA treatment. RNA was extracted from the biopsy 
specimens for CAR RT-PCR semi-quantitative analysis. The GAPDH gene was used as loading control for semi-quantification 
analysis.Genetic Vaccines and Therapy 2007, 5:10 http://www.gvt-journal.com/content/5/1/10
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Furthermore, HDAC inhibitor drugs possess two addi-
tional properties that would complement the anti-neo-
plastic gene therapy strategy. First HDAC inhibitors are
transcriptionally active compounds which enhance the
expression of the therapeutic gene in the transduced cells
[13,15-17,33]. Second, HDAC inhibitor drugs have per se
anti-neoplastic properties [18,19].
Conclusion
The incorporation of HDAC inhibitor drugs into the over-
all scheme in cancer gene therapy clinical trials would
thus seem rational. Pre-clinical studies using VPA and
other HDACi are required in order to further characterize
doses, precise scheduling and to study possible anti-neo-
plastic potentiating effects.
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